Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600E |
Therapy | Dabrafenib + Panitumumab + Trametinib |
Indication/Tumor Type | colon cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E | colon cancer | predicted - sensitive | Dabrafenib + Panitumumab + Trametinib | Case Reports/Case Series | Actionable | In a clinical study, treatment with the combination of Vectibix (panitumumab), Tafinlar (dabrafenib), and Mekinist (trametinib) resulted in a clinical response in a pediatric patient with colon cancer harboring BRAF V600E, as well as TP53 G245S, SMAD4 S504R, and PTEN loss, with decreased liver metastases and reduction in CA-19-9 and BRAF V600E VAF levels in the cell free DNA (PMID: 39626159; NCT02688517). | 39626159 |
PubMed Id | Reference Title | Details |
---|---|---|
(39626159) | Evolution of Rapid Clonal Dynamics and Non-Cross-Resistance in Response to Alternating Targeted Therapy and Chemotherapy in BRAF-V600E-Mutant Colon Cancer. | Full reference... |